Steroid Hormone Action In Female Reproduction

本项目的重点是肌瘤(肌瘤)，并检查与其发病机制、诊断和/或潜在治疗相关的因素。正在进行的工作旨在评估孕酮反应调节剂CDB2914作为治疗子宫肌瘤的效用。我们之前研究了单次剂量的药物对女性月经周期的影响，结果表明，100或200 mg的剂量分别延迟卵泡期和黄体期的卵泡形成和月经沉淀。 来自我们组的两个随机双盲安慰剂对照临床试验显示，与接受安慰剂治疗的女性相比，服用CDB 2914的女性在三个月的时间里每天服用10或20毫克的CDB 2914可以减少肌瘤大小。其中一项研究在第二项为期三个月的研究中显示出持续的疗效。我们还使用基因阵列来评估子宫肌瘤的病理生理学。

This project focuses on leiomyomata (fibroids) and examines factors related to their pathogenesis, diagnosis and/or potential treatment. Ongoing work seeks to evaluate the utility of the progesterone response modulator CDB2914 as a treatment of fibroids. We previously investigated the effect of single doses of the agent on the menstrual cycle in women, and showed that doses of 100 or 200 mg retard folliculogenesis and precipitate menses, in the follicular and luteal phase respectively. Two randomized double-blind placebo-controlled clinical trials from our group showed reduction in fibroid size in women receiving CDB 2914 at a daily dose of 10 or 20 mg for three months, as compared to women receiving placebo. One of these studies showed continued efficacy during a second three-month study. We also are using gene arrays to evaluate the pathophysiology of leiomyomata.